Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review.

Vincenzo Carlomagno Massimiliano Mirabella Matteo Lucchini

Published in: Bioengineering (Basel, Switzerland) (2023)

Cognitive outcomes were evaluated only in a minority of prospective studies on oral DMTs in MS patients with variable findings. More solid and numerous data are present for the S1P modulators. A standardised cognitive evaluation remains a yet unmet need to better clarify the possible positive effect of oral DMTs on cognition.

Keyphrases

multiple sclerosis
current status
white matter
mass spectrometry
small molecule
big data
electronic health record
type diabetes
metabolic syndrome
mild cognitive impairment
skeletal muscle
artificial intelligence
combination therapy
glycemic control
deep learning
smoking cessation